Simon Read Sells 2,777 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,777 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.55, for a total value of $304,220.35. Following the completion of the transaction, the director owned 2,777 shares of the company’s stock, valued at approximately $304,220.35. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $112.41 on Thursday. Dianthus Therapeutics, Inc. has a 52-week low of $19.75 and a 52-week high of $114.55. The firm has a market cap of $6.15 billion, a price-to-earnings ratio of -27.09 and a beta of 1.22. The business’s fifty day moving average is $96.25 and its 200 day moving average is $82.21.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains favorable. Truist Financial raised its price target to $128 and maintained a “buy” rating, while the broader analyst consensus is “Moderate Buy” with an average target of $124.27. HC Wainwright also issued an optimistic earnings outlook, potentially supporting DNTH. HC Wainwright earnings outlook
• Positive Sentiment: Institutional ownership trends were generally supportive. AllianceBernstein, Invesco, American Century and Mirae Asset increased their positions during recent quarters, and institutional investors collectively own approximately 47.5% of the company.
• Neutral Sentiment: Short interest was reported at zero shares as of August 11, with a zero-day days-to-cover ratio. This suggests limited short-selling pressure, but also no meaningful short-squeeze catalyst for DNTH.
• Negative Sentiment: Several insiders sold substantial portions of their holdings near $109-$111. SVP Adam M. Veness sold 20,000 shares for approximately $2.21 million, reducing his position by about 81%. Director Anne McGeorge sold 7,750 shares for roughly $845,000, cutting her holdings by 86%, while Director Simon Read sold 2,777 shares for approximately $304,000 and halved his position. The clustered sales may concern investors because they occurred near the stock’s 52-week high. SEC insider trading filing
• Negative Sentiment: Dianthus recently reported a quarterly loss of $0.90 per share, missing the $0.85 consensus estimate. Although revenue of $0.76 million exceeded the $0.30 million forecast, the company remains unprofitable, with analysts expecting a full-year loss of approximately $3.83 per share.

Analysts Set New Price Targets

Several equities analysts recently commented on DNTH shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Truist Financial increased their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $124.27.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DNTH. First Horizon Corp purchased a new stake in Dianthus Therapeutics in the first quarter valued at approximately $32,000. Global Retirement Partners LLC purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $93,000. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $27,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth $64,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.